Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quarterly results round-up: Beckman still strong overall, as Gen-Probe misses expectations

This article was originally published in Clinica

Executive Summary

Beckman Coulter reported third-quarter revenue of $893.8m, which was up by around 9% compared to the same period last year. The growth was attributed, in part, to the acquired Olympus lab-based diagnostics division. The acquisition helped to considerably bulk up Beckman's chemistry and clinical automation business, which recorded 14% reported growth in sales, at $323.2m. This, in turn, helped to drive, clinical diagnostics revenue, which reached $787.6m (11% reported growth). Geographically, strong sales in Asia-Pacific and emerging markets helped to off-set softness in developed markets. Beckman’s net income for the period was $67m, a significant improvement on Q3 2009 which was impacted by $79.2m in restructuring charges and reported earnings of $1.5m.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel